[go: up one dir, main page]

BRPI0820432B8 - derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados - Google Patents

derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados

Info

Publication number
BRPI0820432B8
BRPI0820432B8 BRPI0820432A BRPI0820432A BRPI0820432B8 BR PI0820432 B8 BRPI0820432 B8 BR PI0820432B8 BR PI0820432 A BRPI0820432 A BR PI0820432A BR PI0820432 A BRPI0820432 A BR PI0820432A BR PI0820432 B8 BRPI0820432 B8 BR PI0820432B8
Authority
BR
Brazil
Prior art keywords
derivatives
formula
alkyl
prophylactic
phenylpyrazole
Prior art date
Application number
BRPI0820432A
Other languages
English (en)
Inventor
Fujino Aya
Nozawa Dai
Ohta Hiroshi
Tatsuzuki Makoto
Masuda Seiji
Chaki Shigeyuki
Kashiwa Shuhei
Tamita Tomoko
Shimazaki Toshiharu
Nakamura Toshio
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI0820432A2 publication Critical patent/BRPI0820432A2/pt
Publication of BRPI0820432B1 publication Critical patent/BRPI0820432B1/pt
Publication of BRPI0820432B8 publication Critical patent/BRPI0820432B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de fenilpirazol. a presente invenção refere-se a um agente profilático ou terapêutico para demência, doença de alzheimer, distúrbio de hiperatividade com déficit de atenção, esquizofrenia, distúrbios alimentares, obesidade, diabetes, hiperlipidemia, distúrbios do sono, narcolepsia, síndrome da apneia do sono, distúrbio do ritmo circadiano, depressão, rinite alérgica ou outras doenças. um derivado de fenilpirazol representado pela fórmula (1) ou um sal farmaceuticamente aceitável do mesmo: formula 1 em que r1 e r2, que podem ser iguais ou diferentes, representam cada um c1-c6 alquila ou c3-c8 cicloalquila, ou r1 e r2 são ligados um ao outro junto com seu átomo de nitrogênio adjacente para formar um anel heterocíclico saturado de 4 a 7 membros (em que o dito anel heterocíclico saturado pode ser substituído com halogênio ou c1-c6 alquila), n representa um numero inteiro de 0 a 2. t representa um átomo de hidrogênio, halogênio ou c1-c6 alquila, e r representa a fórmula (i): fórmula 2 ou similar}.
BRPI0820432A 2007-11-13 2008-11-13 derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados BRPI0820432B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Publications (3)

Publication Number Publication Date
BRPI0820432A2 BRPI0820432A2 (pt) 2015-05-26
BRPI0820432B1 BRPI0820432B1 (pt) 2020-01-14
BRPI0820432B8 true BRPI0820432B8 (pt) 2021-05-25

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820432A BRPI0820432B8 (pt) 2007-11-13 2008-11-13 derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados

Country Status (25)

Country Link
US (3) US7888354B2 (pt)
EP (1) EP2221298B1 (pt)
JP (2) JP4543344B2 (pt)
KR (1) KR101571176B1 (pt)
CN (1) CN101855211B (pt)
AU (1) AU2008321823B2 (pt)
BR (1) BRPI0820432B8 (pt)
CA (1) CA2705502C (pt)
CY (1) CY1114877T1 (pt)
DK (1) DK2221298T3 (pt)
ES (1) ES2436146T3 (pt)
HK (1) HK1145834A1 (pt)
HR (1) HRP20131060T1 (pt)
IL (2) IL205509A (pt)
MX (1) MX2010005225A (pt)
MY (1) MY173546A (pt)
NZ (1) NZ585661A (pt)
PH (1) PH12012501917A1 (pt)
PL (1) PL2221298T3 (pt)
PT (1) PT2221298E (pt)
RS (1) RS53125B (pt)
RU (1) RU2480456C2 (pt)
SI (1) SI2221298T1 (pt)
WO (1) WO2009063953A1 (pt)
ZA (1) ZA201003111B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
AU2008321823B2 (en) * 2007-11-13 2013-03-07 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体
CA2858342A1 (en) * 2011-12-08 2013-06-13 Taisho Pharmaceutical Co., Ltd. Phenylpyrrole derivative
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
ES2707323T3 (es) * 2012-12-07 2019-04-03 Chemocentryx Inc Diazol lactamas
CA2898015A1 (en) 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases
KR102370704B1 (ko) 2016-04-07 2022-03-03 케모센트릭스, 인크. Pd-1 억제제 또는 pd-l1 억제제와 조합하여 ccr1 길항제를 투여하여 종양 총량을 감소시키는 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
PT1311482E (pt) 2000-08-08 2007-04-30 Ortho Mcneil Pharm Inc Ariloxipiperidinas não imidazólicas como ligandos do receptor h3
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
BR0205829A (pt) * 2001-03-16 2005-03-08 Abbott Lab Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
CA2529790A1 (en) 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
EP1761496A2 (en) 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
ES2534605T3 (es) 2004-08-23 2015-04-24 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
ATE517882T1 (de) 2004-10-19 2011-08-15 Hoffmann La Roche Chinolinderivate
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
CA2588867A1 (en) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
KR20070091007A (ko) 2004-12-07 2007-09-06 글락소 그룹 리미티드 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도
US7790720B2 (en) 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
CA2602234C (en) 2005-04-01 2014-01-14 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DK1988777T3 (da) 2006-02-09 2012-01-16 Athersys Inc Pyrazoler til behandling af fedme og andre cns-lidelser
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
EP2134673A1 (en) * 2007-04-12 2009-12-23 DSM Fine Chemicals Austria Nfg GmbH & Co KG Improved process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation
AU2008321823B2 (en) * 2007-11-13 2013-03-07 Taisho Pharmaceutical Co., Ltd. Phenylpyrazole derivatives

Also Published As

Publication number Publication date
IL205509A0 (en) 2010-12-30
AU2008321823A1 (en) 2009-05-22
CN101855211B (zh) 2013-06-12
JP5375639B2 (ja) 2013-12-25
BRPI0820432A2 (pt) 2015-05-26
BRPI0820432B1 (pt) 2020-01-14
RS53125B (en) 2014-06-30
IL236083A0 (en) 2015-01-29
HK1145834A1 (en) 2011-05-06
IL236083A (en) 2016-12-29
EP2221298A4 (en) 2011-09-21
JP4543344B2 (ja) 2010-09-15
MX2010005225A (es) 2010-05-27
NZ585661A (en) 2012-04-27
HRP20131060T1 (hr) 2013-12-20
CN101855211A (zh) 2010-10-06
DK2221298T3 (da) 2013-11-18
IL205509A (en) 2015-09-24
JPWO2009063953A1 (ja) 2011-03-31
RU2010123924A (ru) 2011-12-20
MY173546A (en) 2020-02-04
CY1114877T1 (el) 2016-12-14
US8193176B2 (en) 2012-06-05
CA2705502C (en) 2016-01-26
EP2221298B1 (en) 2013-11-06
WO2009063953A1 (ja) 2009-05-22
US20110065667A1 (en) 2011-03-17
KR101571176B1 (ko) 2015-11-23
EP2221298A1 (en) 2010-08-25
US8183387B2 (en) 2012-05-22
ZA201003111B (en) 2011-08-31
CA2705502A1 (en) 2009-05-22
ES2436146T3 (es) 2013-12-27
PT2221298E (pt) 2013-12-03
US20100267687A1 (en) 2010-10-21
KR20100083795A (ko) 2010-07-22
PH12012501917A1 (en) 2014-10-17
US7888354B2 (en) 2011-02-15
AU2008321823B2 (en) 2013-03-07
SI2221298T1 (sl) 2013-12-31
US20110065668A1 (en) 2011-03-17
RU2480456C2 (ru) 2013-04-27
JP2010143943A (ja) 2010-07-01
PL2221298T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
BRPI0820432B8 (pt) derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados
AR035722A1 (es) Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos
BR112014003496A2 (pt) derivado heterocíclico e fármaco
MX2011008336A (es) Derivados de dihidroquinolinona.
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BRPI0417208A (pt) derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona
BR112012007069A2 (pt) derivado de fenol
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
BRPI0515851A (pt) composto de pirimidona
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
BR112014004275A2 (pt) derivados de isoxazolina como compostos inseticidas
DK1893589T3 (da) Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
AR062295A1 (es) Compuesto de 1h-quinolin-4-ona, procedimientos para su preparacion y composicion farmaceutica
GT200600490A (es) Derivados de isoquinolina y benzo[h]isoquinolina su preparación y su utilización en terapéutica
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
WO2009064836A3 (en) Kynurenine-aminotransferase inhibitors
DK1384476T3 (da) Azolylcarbinolderivater af aryl (eller heteroaryl) til behandling af åndedrætssygdomme
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
BRPI0909824A2 (pt) 2-aminoquinolinas
ATE499099T1 (de) Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
WO2008126886A1 (ja) インドール又はインドリン誘導体
TH120271A (th) สารอนุพันธ์ไดไฮโดรควิโนลิโนน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2800 DE 03-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.